0.00
—
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Viaderma
Its shares trade under the ticker VDRM. It has been listed since 10 June 2008. In the fiscal year to 31 December 2024, it reported revenue of $450,500 and a net loss of $3.9m. At that date it held total assets of $3.6m and shareholders' equity of −$3.7m.
ViaDerma, Inc. is engaged in the manufacturing and sales of pharmaceutical related products. The company is headquartered in Marina Del Rey, California. The company went IPO on 2008-06-10. The Company’s lead product is a topical antibiotic, which is focused on being sold under the brand name Vitastem. In addition to licensing its proprietary transdermal technologies, its lead product, Vitastem, is available for treating multiple skin conditions and ailments. The firm also has products in development in fields, such as anti-aging skin care, pain management, hair-loss, and toenail fungus. The products are based on a delivery system technology that allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy. The Company’s products are sold to local medical practitioners and patients in clinics primarily in the Los Angeles, California area. The Company’s subsidiary is ViaDerma, II Inc.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Jun 2008
- Employees
- 75
- Website
- viadermalicensing.com ↗
Leadership
Pay as last reported
- Dr. Chris OtikoChairman of the Board, since 2014
- Rui Sheng LiuPresident, Chief Executive Officer, Director, since 2009$167,321
- Qing Hua LinChief Financial Officer, Director, since 2011$4,455
- Shaowen ZhangManager - Production$27,684
- Baotang ZhaoChief Sales Officer$28,766
- Zhang XieCorporate Secretary, Director, since 2011$9,178
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vitastem is a topical antibiotic for skin conditions with rapid mass transfer technology.
- ViaDerma, Inc. has 75 employees focused on pharmaceutical manufacturing and sales.
- Los Angeles area clinics are primary sales locations for Vitastem and transdermal products.
Weaknesses
- ViaDerma, II Inc. is a subsidiary with limited product development scope.
- Vitastem is the lead product with no other branded pharmaceuticals in the portfolio.
- The company's focus on Los Angeles limits broader market reach.
Opportunities
- Anti-aging skin care products in development could expand market share.
- Pain management and hair-loss products may attract new customer segments.
- Toenail fungus treatments offer a growing niche in dermatology.
Threats
- Vitastem's reliance on a single product line poses market vulnerability.
- Limited employee count of 75 may hinder rapid innovation.
- The Los Angeles sales focus restricts national expansion opportunities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.